Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 3/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753543 | 0.83 | MAPK1 (0.42) | HDAC11ITKALDH1A1HTTKDM4E | |
| SCHEMBL6489873 | 0.82 | ITK (0.41) | ITKTAS1R3TAS1R1DRD2KMT2A | |
| SCHEMBL6489729 | 0.82 | ITK (0.49) | ITKTAS1R3TAS1R1 | |
| SCHEMBL5752672 | 0.80 | HDAC11 (0.41) | HDAC11ALDH1A1HTTKDM4EPKM | |
| SCHEMBL5755838 | 0.79 | BRAF (0.44) | HDAC11ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL5756543 | 0.77 | HDAC11 (0.39) | HDAC11ITKALDH1A1HTTKDM4E | |
| SCHEMBL5754686 | 0.77 | KDR (0.43) | HDAC11ITKKDM4EMAPT | |
| SCHEMBL5757017 | 0.75 | HDAC11 (0.43) | HDAC11ITKALDH1A1KDM4EPKM | |
| SCHEMBL5752805 | 0.75 | TSHR (0.47) | HDAC11ALDH1A1HTTDRD2KDM4E | |
| SCHEMBL6478728 | 0.75 | TACR3 (0.34) | HDAC11ITKALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | HDAC11 1178/4885ITK 392/4885TAS1R3 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.